Transcriptomic analysis in PDX mammary carcinoma after CDK4/6 inhibition. Homo sapiens

NIAID Data Ecosystem2026-03-10 收录

CDK4/6抑制剂药物作用

PDX肿瘤基因表达

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA387166 数据链接链接失效反馈

官方服务：

资源简介：

We measured changes in expression of 20,812 human genes PDX tumors growing in mice after treatment with abemaciclib Overall design: Examination of changes in gene expression

创建时间：

2017-05-18

Gene expression analysis of treatment-naïve hormone receptor-positive metastistic breast cancer. Gene expression analysis of treatment-naïve hormone receptor-positive metastistic breast cancer

癌症生物标志物

CDK4/6抑制剂药物作用

A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to letrozole Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have de

NIAID Data Ecosystem40

Data_Sheet_1_Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.docx

肾上腺皮质癌靶向治疗

CDK4/6抑制剂药物作用

Adrenocortical carcinomas (ACC) are aggressive tumors with a heterogeneous prognosis and limited therapeutic options for advanced stages. This study aims to identify novel drug targets for a personali

NIAID Data Ecosystem20

RBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

癌症预后生物标志物

CDK4/6抑制剂药物作用

Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survi

NIAID Data Ecosystem20

RNAseq based trascript profilling of MCF7-xenograft mice treated with one of three CDK4/6 inhibitiors

CDK4/6抑制剂药物作用

乳腺癌基因表达

We compare differences in gene expression induced after treating MCF7-xenograft mice with either ribociclib, palbociclib, or abemacicilb daily for 4 days. Overall design: Mice were engrafted with MCF7

NIAID Data Ecosystem30

RBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

癌症代谢组学

CDK4/6抑制剂药物作用

This is the serum metabolomics data of hormone receptor positive advanced cancer patients before receiving CDK4/6 inhibitor treatment. The code for analysis is attached.

NIAID Data Ecosystem20

Transcriptomic analysis in PDX mammary carcinoma after CDK4/6 inhibition. Homo sapiens

资源简介：

相关数据集